RxDoctor Payments Data

Adam Rubin, MD

Nephrology · Wyomissing, PANPI 1881634020

Payments from drug & device makers

$622in general payments, 2019–2025

Across 29 payments — averaging $21.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$102
  • Otsuka America Pharmaceutical, Inc.$70
  • Endologix LLC$69
  • Amgen$67
  • Fresenius USA Marketing, Inc.$60
  • AstraZeneca$55
  • plus $199 from 8 others

What the payments were for

  • Food & beverage$622100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$622 in reported general payments places this provider in the 45th percentile of 586 nephrology providers in Pennsylvania.

See all nephrology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$349,767
Medicare patients
513
Services billed
5,852

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide42$159,463
KerendiaFinerenone49$60,022
ProcritEpoetin Alfa11$38,325
VeltassaPatiromer Calcium Sorbitex29$34,303
JardianceEmpagliflozin26$30,704
AuryxiaFerric Citrate21$27,632
JanuviaSitagliptin Phosphate21$22,687
FarxigaDapagliflozin Propanediol27$14,757
MounjaroTirzepatide13$13,673
Lanthanum Carbonate16$12,366
Sevelamer Carbonate61$11,132
Cinacalcet Hcl30$8,862
EntrestoSacubitril/Valsartan13$8,357
Febuxostat38$6,865
Potassium Citrate ErPotassium Citrate58$5,353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$60$159,46342 claims
BayerKerendia$102$60,02249 claims
Johnson & JohnsonProcrit$44$38,32511 claims
AstraZenecaFarxiga$55$14,75727 claims
NovartisEntresto$17$8,35713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 586 nephrology providers in Pennsylvania.

Other nephrology in Wyomissing

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →